• Policy
• Daewoong wins nod for first generic version of Ibrance tab
• by Lee, Tak-Sun Oct 8, 2024 05:49am

• Company
• Eisai Korea signs Alzheimer's MOU with the Korean Dementia
• by Whang, byung-woo Oct 8, 2024 05:49am

• Company
• Galderma Korea appoints Jai Hyuk Lee as new GM
• by Whang, byung-woo Oct 8, 2024 05:48am

• Policy
• Drugs for NSCLC harboring MET alterations pass CDRC review
• by Lee, Tak-Sun Oct 7, 2024 05:48am

• Company
• Yuhan·Dongwha as potential distributor for Bayer's OTC drug
• by Nho, Byung Chul Oct 7, 2024 05:48am

• Policy
• 'Qarziba' to be reconsidered for the DREC review in KOR
• by Lee, Tak-Sun Oct 7, 2024 05:48am

• Opinion
• [Reporter’s View]Contradictions in the CSO reporting system
• by Kim, Jin-Gu Oct 7, 2024 05:48am

• Company
• Darzalex seeks reimbursement extensions again in KOR
• by Whang, byung-woo Oct 7, 2024 05:48am

• Company
• No new news on reimb extension of Lorviqua for 4mths
• by Eo, Yun-Ho Oct 7, 2024 05:48am

• Company
• Camzyos’s reimbursement decision imminent
• by Moon, sung-ho Oct 4, 2024 04:38am